PMID- 34281885
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 41
IP  - 8
DP  - 2021 Aug
TI  - Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 
      2+ Invasive Breast Cancer.
PG  - 4143-4149
LID - 10.21873/anticanres.15217 [doi]
AB  - BACKGROUND/AIM: With advances in anti-HER2 treatment and improved prognoses of 
      HER2-positive breast cancer, the American Society of Clinical Oncology and the 
      American Society of Pathologists (ASCO/CAP) have revised the HER2 diagnostic 
      guidelines several times. We examined how to respond clinically to the revisions 
      of the interpretation of the immunohistochemistry (IHC) method. PATIENTS AND 
      METHODS: We re-evaluated 254 patients diagnosed as HER2 IHC equivocal, who 
      underwent fluorescence in situ hybridization (FISH) before and after the IHC 
      diagnostic criteria update in 2013. RESULTS: Twenty of 131 (15.3%) IHC equivocal 
      cases by the ASCO/CAP 2007 guideline were IHC score 3+ and one of 20 (0.76%) was 
      negative for FISH. Five of 123 (4.1%) IHC equivocal cases by the ASCO/CAP 2013 
      guideline were negative for IHC as per the 2007 guideline and four were positive 
      for FISH. CONCLUSION: After revision of the ASCO/CAP 2013 guideline, 3.3% of 
      HER2-negative cases before the revision should have received anti-HER2 treatment.
CI  - Copyright (c) 2021 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Yamada, Mai
AU  - Yamada M
AD  - Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Kubo, Makoto
AU  - Kubo M
AD  - Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan mkubo@surg1.med.kyushu-u.ac.jp.
FAU - Yamamoto, Hidetaka
AU  - Yamamoto H
AD  - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Yamashita, Nami
AU  - Yamashita N
AD  - Department of Surgery and Science, Kyushu University, Fukuoka, Japan.
FAU - Kai, Masaya
AU  - Kai M
AD  - Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Zaguirre, Karen
AU  - Zaguirre K
AD  - Institute of Surgery, St. Luke's Medical Center, Quezon, Philippines.
FAU - Kaneshiro, Kazuhisa
AU  - Kaneshiro K
AD  - Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Shimazaki, Akiko
AU  - Shimazaki A
AD  - Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Hayashi, Saori
AU  - Hayashi S
AD  - Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Kawaji, Hitomi
AU  - Kawaji H
AD  - Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Mori, Masaki
AU  - Mori M
AD  - Department of Surgery and Science, Kyushu University, Fukuoka, Japan.
FAU - Oda, Yoshinao
AU  - Oda Y
AD  - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Nakamura, Masafumi
AU  - Nakamura M
AD  - Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Breast Neoplasms/*diagnosis/drug therapy/metabolism/surgery
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Practice Guidelines as Topic
MH  - Receptor, ErbB-2/antagonists & inhibitors/*metabolism
OTO - NOTNLM
OT  - HER2 diagnosis
OT  - IHC/HER2 equivocal
OT  - revision of ASCO/CAP guideline
EDAT- 2021/07/21 06:00
MHDA- 2021/07/30 06:00
CRDT- 2021/07/20 06:09
PHST- 2021/05/22 00:00 [received]
PHST- 2021/06/12 00:00 [revised]
PHST- 2021/06/17 00:00 [accepted]
PHST- 2021/07/20 06:09 [entrez]
PHST- 2021/07/21 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
AID - 41/8/4143 [pii]
AID - 10.21873/anticanres.15217 [doi]
PST - ppublish
SO  - Anticancer Res. 2021 Aug;41(8):4143-4149. doi: 10.21873/anticanres.15217.